Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges

scientific article published on 30 June 2016

Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2016.06.058
P698PubMed publication ID27373596

P2093author name stringQin Yan
Yali Qin
Zishu Pan
Longyun Chen
Mingzhou Chen
Linjuan Wu
P2860cites workEvaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleQ27473287
Ligation-independent cloning of PCR products (LIC-PCR)Q29618962
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Q30370147
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesQ33657931
Expression, purification and characterization of enterovirus-71 virus-like particlesQ33788579
Neurologic complications in children with enterovirus 71 infectionQ33875092
Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system.Q33908518
Clinical features, diagnosis, and management of enterovirus 71.Q34144978
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsQ34273164
Vesicular stomatitis virus-based vaccines against Lassa and Ebola virusesQ34459935
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg virusesQ34598925
An overview of the evolution of enterovirus 71 and its clinical and public health significanceQ34635602
Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alphaQ34717937
Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virusQ34742846
Biophysical studies of vesicular stomatitis virusQ35144870
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.Q35635393
Vesicular stomatitis virus: re-inventing the bulletQ35761892
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virusQ36239796
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceQ36423935
Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 proteinQ36672543
In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculationQ37354600
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapyQ37418123
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.Q37714030
Virology, epidemiology, pathogenesis, and control of enterovirus 71.Q37801742
Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expressionQ39233488
Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009.Q39495121
Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathologyQ39753151
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialQ40144208
The role of TH1 and TH2 subsets in human infectious diseasesQ40742872
Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelopeQ40898990
Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.Q44201038
Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice.Q45362744
Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challengeQ45396589
Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virusQ45734536
Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences.Q47736273
Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71Q95821973
P433issue35
P407language of work or nameEnglishQ1860
P921main subjectvesicular stomatitisQ11549084
P304page(s)4196-4204
P577publication date2016-06-30
P1433published inVaccineQ7907941
P1476titleVesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges
P478volume34

Reverse relations

cites work (P2860)
Q88883557Antivirals and vaccines for Enterovirus A71
Q45324939Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice
Q54247724Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.
Q47553138Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.
Q92335586Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Search more.